Initialization of Methadone in Primary Care, Randomized Intervention Research for Preventing HCV Transmission Practices
Information source: French National Agency for Research on AIDS and Viral Hepatitis
Information obtained from ClinicalTrials.gov on October 19, 2009 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hepatitis C; Substance Dependence; Methadone
Intervention: Methadone (Drug)
Phase: Phase 3
Status: Not yet recruiting
Sponsored by: French National Agency for Research on AIDS and Viral Hepatitis Official(s) and/or principal investigator(s): Alain Morel, MD, Principal Investigator, Affiliation: CSST Le trait d'union, 154 rue du vieux pont de Sèvres, 92100 Boulogne, France Patrizia Carrieri, PHD, Study Director, Affiliation: ORS PACA - INSERM-IRD UMR912, 23, rue Stanislas Torrents, 13006 Marseille
Summary
The rapid scale up of opioid substitution treatment (OST) for drug users mainly achieved
through the possibility of prescribing buprenorphine in primary care has been successful in
reducing HIV prevalence among drug users but still inadequate for reducing the spread of
HCV. To date, methadone in France can only be initialised in drug centres but GPs can
prescribe methadone after stabilisation of dosages.
This study was born as an answer to a request from the French Minister of Health that
supports the initialisation of methadone in primary care in order to improve coverage by OST
(now 70%) in Intravenous drug users.
Clinical Details
Official title: Initialization of Methadone in Primary Care; a Randomized Intervention Research for Preventing HCV Transmission Practices. ANRS Methaville
Study design: Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Primary outcome: prevalence of daily injectors after one year of treatment will be compared between arms.
Secondary outcome: - prevalence of other addictive behavioursadherence to treatment improvement in quality of life, psychiatric comorbidities, social insertion, reduction in criminal acts cost-effectiveness surveillance of severe adverse events and overdose cases in each arm
Detailed description:
The rapid scale up of opioid substitution treatment (OST) for drug users mainly achieved
through the possibility of prescribing buprenorphine in primary care has been successful in
reducing HIV prevalence among drug users but still inadequate for reducing the spread of
HCV. To date, methadone in France can only be initialised in drug centres but GPs can
prescribe methadone after stabilisation of dosages.
This study was born as an answer to a request from the French Minister of Health that
supports the initialisation of methadone in primary care in order to improve coverage by OST
(now 70%) in Intravenous drug users.
Eligibility
Minimum age: 18 Years.
Maximum age: 70 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- 18 to 70 years patients needing methadone for their opioid dependence who are either
naives of methadone treatment (prescribed) since at least 1 month
- need to switch from buprenorphine to methadone treatment
- negative test for pregnancy
Exclusion Criteria:
- co-dependent on alcohol and benzodiazepines,
- inmates,
- pregnant women,
- individual in irregular situation or who cannot be joined by phone.
Locations and Contacts
CSST Le trait d'union, Boulogne 92100, France
Additional Information
Starting date: September 2008
Ending date: September 2010
Last updated: June 18, 2008
|